Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

[1]  Matthias J. Müller,et al.  AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. , 2014, Pharmacopsychiatry.

[2]  J. Brockmöller,et al.  Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function , 2013, Molecular Psychiatry.

[3]  M R Wilkinson,et al.  A Clinician‐Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record , 2012, Clinical pharmacology and therapeutics.

[4]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[5]  R. Altman,et al.  Implementing Personalized Medicine: Development of a Cost‐Effective Customized Pharmacogenetics Genotyping Array , 2012, Clinical pharmacology and therapeutics.

[6]  E. Lyon,et al.  Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy , 2012, Genetics in Medicine.

[7]  M. Relling,et al.  Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods , 2012, Clinical pharmacology and therapeutics.

[8]  J. Lieberman,et al.  The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. , 2012, Genetic testing and molecular biomarkers.

[9]  E. Clayton,et al.  Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.

[10]  L Gong,et al.  The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy , 2012, Clinical pharmacology and therapeutics.

[11]  Edward O'Brien,et al.  Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial , 2012, The Lancet.

[12]  J. Kelsoe,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing , 2012, Clinical pharmacology and therapeutics.

[13]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing , 2012, Clinical pharmacology and therapeutics.

[14]  M. Droździk,et al.  CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers , 2012, European Journal of Clinical Pharmacology.

[15]  A. de Boer,et al.  The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting , 2012, Pharmacogenetics and genomics.

[16]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.

[17]  J. Weide,et al.  Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients , 2011, The Pharmacogenomics Journal.

[18]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.

[19]  Matthias J. Müller,et al.  AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 , 2011, Pharmacopsychiatry.

[20]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy , 2011, Clinical pharmacology and therapeutics.

[21]  S. Curry,et al.  Prolonged Toxicity after Amitriptyline Overdose in a Patient Deficient in CYP2D6 Activity , 2011, Journal of Medical Toxicology.

[22]  G. McMillin,et al.  Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infiniti™ and Luminex CYP2C19 panels. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[23]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[24]  T. Skaar,et al.  Gene copy number variations: it is important to determine which allele is affected. , 2011, Pharmacogenomics.

[25]  R. Desnick,et al.  Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness , 2011, The Pharmacogenomics Journal.

[26]  A. Shuldiner,et al.  The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. , 2011, American heart journal.

[27]  M. Relling,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapeutics.

[28]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[29]  Eun-Young Kim,et al.  Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[30]  Douglas Woo,et al.  Extrapyramidal symptoms with concomitant use of amitriptyline and amiodarone in an elderly patient. , 2010, The American journal of geriatric pharmacotherapy.

[31]  Barbara Zehnbauer,et al.  Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. , 2010, The Journal of molecular diagnostics : JMD.

[32]  A. Zackrisson,et al.  High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases , 2010, Clinical pharmacology and therapeutics.

[33]  N. Pedersen,et al.  Association between CYP2C19 polymorphism and depressive symptoms , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[34]  A. Kastrati,et al.  Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy , 2010, Journal of thrombosis and haemostasis : JTH.

[35]  A. Shuldiner,et al.  Genotyping: one piece of the puzzle to personalize antiplatelet therapy. , 2010, Journal of the American College of Cardiology.

[36]  J. Lindemans,et al.  The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients , 2010, The Pharmacogenomics Journal.

[37]  G. Kearns,et al.  Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect , 2010, Drug Metabolism and Disposition.

[38]  Zeruesenay Desta,et al.  Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients , 2010, Journal of clinical pharmacology.

[39]  P. Farndon,et al.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. , 2010, British journal of clinical pharmacology.

[40]  A. Kastrati,et al.  Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.

[41]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[42]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[43]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[44]  F. Chiafari,et al.  DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping , 2009, CNS Spectrums.

[45]  M. Ingelman-Sundberg,et al.  Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects , 2008, European Journal of Clinical Pharmacology.

[46]  J. Lindemans,et al.  Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients , 2008, Molecular Psychiatry.

[47]  B. Laird,et al.  Management of cancer pain: basic principles and neuropathic cancer pain. , 2008, European journal of cancer.

[48]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte , 2008, Clinical pharmacology and therapeutics.

[49]  M. Ingelman-Sundberg,et al.  Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. , 2008, British journal of clinical pharmacology.

[50]  A. Hofman,et al.  Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. , 2008, British journal of clinical pharmacology.

[51]  H. Refsum,et al.  Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients , 2008, Clinical pharmacology and therapeutics.

[52]  A. Gaedigk,et al.  The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype , 2008, Clinical pharmacology and therapeutics.

[53]  J. Kirchheiner.  CYP2D6 Phenotype Prediction From Genotype: Which System Is the Best? , 2008, Clinical pharmacology and therapeutics.

[54]  J. Farrar,et al.  Pharmacologic management of neuropathic pain: Evidence-based recommendations , 2007, PAIN.

[55]  M. Rychlik-Sych,et al.  CYP2D6 phenotyping with dextromethorphan. , 2007, Pharmacological reports : PR.

[56]  D. Flockhart,et al.  The Star‐Allele Nomenclature: Retooling for Translational Genomics , 2007, Clinical pharmacology and therapeutics.

[57]  A. Sajantila,et al.  A Fatal Doxepin Poisoning Associated With a Defective CYP2D6 Genotype , 2007, The American journal of forensic medicine and pathology.

[58]  P. Gillman.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated , 2007, British journal of pharmacology.

[59]  A. Seeringer,et al.  Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. , 2007, Biochimica et biophysica acta.

[60]  J. Schellens,et al.  Pharmacogenetic Screening of the Gene Deletion and Duplications of CYP2D6 , 2007, Drug metabolism reviews.

[61]  J. Gallinat,et al.  Association of CYP2D6 genotypes and personality traits in healthy individuals. , 2006, Journal of clinical psychopharmacology.

[62]  P. Baumann,et al.  Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. , 2006, Pharmacopsychiatry.

[63]  Soo-Youn Lee,et al.  Sequence-based CYP2D6 Genotyping in the Korean Population , 2006, Therapeutic drug monitoring.

[64]  A. Sajantila,et al.  CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. , 2006, Forensic science international.

[65]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[66]  Nicolas Peyret,et al.  The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. , 2005, Journal of biomolecular techniques : JBT.

[67]  M. Feldman,et al.  Clines, Clusters, and the Effect of Study Design on the Inference of Human Population Structure , 2005, PLoS genetics.

[68]  J. Weide,et al.  Metabolic Ratios of Psychotropics as Indication of Cytochrome P450 2D6/2C19 Genotype , 2005, Therapeutic drug monitoring.

[69]  J. Brockmöller,et al.  Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets , 2005, Pharmacogenetics and genomics.

[70]  M. Rhodes,et al.  Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. , 2005, Mutation research.

[71]  S. Leucht,et al.  Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. , 2005, Clinical chemistry.

[72]  B Müller-Oerlinghausen,et al.  The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry , 2004, Pharmacopsychiatry.

[73]  C. Ki,et al.  A Case Report of a Poor Metabolizer of CYP2D6 Presented with Unusual Responses to Nortriptyline Medication , 2004, Journal of Korean medical science.

[74]  S. Leucht,et al.  Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. , 2004, Clinical chemistry.

[75]  E. Haffen,et al.  Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients , 2004, Human psychopharmacology.

[76]  Matthias J. Müller,et al.  Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting , 2004, European Journal of Clinical Pharmacology.

[77]  R. Holley-Shanks,et al.  Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. , 2004, Pharmacogenetics.

[78]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[79]  P. Riederer,et al.  Therapeutic Monitoring of Psychotropic Drugs: An Outline of the AGNP-TDM Expert Group Consensus Guideline , 2004, Therapeutic drug monitoring.

[80]  M. Thase.  Achieving remission and managing relapse in depression. , 2003, The Journal of clinical psychiatry.

[81]  J. Sasse,et al.  Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. , 2003, Pharmacogenetics.

[82]  A. Bozkurt,et al.  Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. , 2003, British journal of clinical pharmacology.

[83]  K. Wernecke,et al.  Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics , 2003, Journal of clinical psychopharmacology.

[84]  L. Bertilsson,et al.  Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. , 2003, British journal of clinical pharmacology.

[85]  W. Koch,et al.  Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. , 2003, Clinical chemistry.

[86]  M. Feldman,et al.  Genetic Structure of Human Populations , 2002, Science.

[87]  E. Jaźwińska-Tarnawska,et al.  CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population , 2002, European Journal of Clinical Pharmacology.

[88]  J. Brockmöller,et al.  Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. , 2002, Pharmacogenetics.

[89]  M. Okawa,et al.  The Impact of CYP2C19 and CYP2D6 Genotypes on Metabolism of Amitriptyline in Japanese Psychiatric Patients , 2002, Journal of clinical psychopharmacology.

[90]  C. Hiemke,et al.  The N-Demethylation of the Doxepin Isomers Is Mainly Catalyzed by the Polymorphic CYP2C19 , 2002, Pharmaceutical Research.

[91]  R. Zhu,et al.  The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects , 2002, European Journal of Clinical Pharmacology.

[92]  M. Okawa,et al.  The Effect of CYP2C19 and CYP2D6 Genotypes on the Metabolism of Clomipramine in Japanese Psychiatric Patients , 2001, Journal of clinical psychopharmacology.

[93]  B. Pollock,et al.  CYP2D6 Genotyping with Oligonucleotide Microarrays and Nortriptyline Concentrations in Geriatric Depression , 2001, Neuropsychopharmacology.

[94]  R. A. Zeeuw,et al.  The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers , 2001, European Journal of Clinical Pharmacology.

[95]  S. Kasper,et al.  CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages , 2001, Acta psychiatrica Scandinavica.

[96]  K. Brøsen,et al.  Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6 , 2001, European Journal of Clinical Pharmacology.

[97]  D. Touw,et al.  Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse events. , 2001, British journal of clinical pharmacology.

[98]  J. Brockmöller,et al.  CYP2D6 Genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting , 2000, AAPS PharmSci.

[99]  M. S. Ching,et al.  Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. , 2000, Pharmacogenetics.

[100]  T. Someya,et al.  Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. , 2000, Pharmacology & toxicology.

[101]  C Peter N Watson.  The Treatment of Neuropathic Pain: Antidepressants and Opiodis , 2000, The Clinical journal of pain.

[102]  T. Someya,et al.  Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. , 2000, Journal of clinical psychopharmacology.

[103]  C. Eap,et al.  Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. , 2000, Therapeutic drug monitoring.

[104]  L. Bertilsson,et al.  Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. , 1999, Journal of clinical psychopharmacology.

[105]  P. Dayer,et al.  A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. , 1999, The Journal of pharmacology and experimental therapeutics.

[106]  W. Potter,et al.  Metabolism of Tricyclic Antidepressants , 1999, Cellular and Molecular Neurobiology.

[107]  L. Bertilsson,et al.  Pharmacokinetics of nortriptyline and its 10‐hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes , 1998, Clinical pharmacology and therapeutics.

[108]  P. Dayer,et al.  Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. , 1998, The Journal of pharmacology and experimental therapeutics.

[109]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[110]  P. Dayer,et al.  An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. , 1998, Pharmacogenetics.

[111]  M. Kosel,et al.  Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. , 1998, Pharmacopsychiatry.

[112]  K. Chiba,et al.  Effects of genetic defects in the CYP2C19 gene on the N‐demethylation of imipramine, and clinical outcome of imipramine therapy , 1997, Psychiatry and clinical neurosciences.

[113]  J. Goldstein,et al.  Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. , 1997, The Journal of pharmacology and experimental therapeutics.

[114]  K. Brøsen,et al.  Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4 , 1997, Clinical pharmacology and therapeutics.

[115]  L. Bertilsson,et al.  Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state , 1997, Psychiatry and clinical neurosciences.

[116]  T Ishizaki,et al.  Genotyping of S‐mephenytoin 4′‐hydroxylation in an extended Japanese population , 1996, Clinical pharmacology and therapeutics.

[117]  K. Brøsen,et al.  Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study. , 1996, Pharmacogenetics.

[118]  R. Blouin,et al.  The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry , 1996, Clinical pharmacology and therapeutics.

[119]  K. Chiba,et al.  Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. , 1996, Journal of clinical psychopharmacology.

[120]  L. Bertilsson,et al.  Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype , 1996, Psychopharmacology.

[121]  R. Post,et al.  The emerging role of cytochrome P450 3A in psychopharmacology. , 1995, Journal of clinical psychopharmacology.

[122]  L. Bertilsson,et al.  Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. , 1995, Pharmacogenetics.

[123]  J. Goldstein,et al.  A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. , 1995, Pharmacogenetics.

[124]  W. Shen.  Cytochrome P450 Monooxygenases and Interactions of Psychotropic Drugs: A Five-Year Update , 1995, International journal of psychiatry in medicine.

[125]  M. Ingelman-Sundberg,et al.  Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.

[126]  K. Brøsen,et al.  Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. , 1995, British journal of clinical pharmacology.

[127]  A. El‐Yazigi,et al.  Steady‐State Kinetics of Fluoxetine and Amitriptyline in Patients Treated with a Combination of These Drugs as Compared with Those Treated with Amitriptyline Alone , 1995, Journal of clinical pharmacology.

[128]  K. Chiba,et al.  Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes. , 1994, The Journal of pharmacology and experimental therapeutics.

[129]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[130]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[131]  K. Brøsen,et al.  Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms , 1994, Clinical pharmacology and therapeutics.

[132]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[133]  E. Skjelbo,et al.  The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study. , 1993, British journal of clinical pharmacology.

[134]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[135]  R. Branch,et al.  Genetically determined drug‐metabolizing activity and desipramine‐associated cardiotoxicity: A case report , 1993, Clinical pharmacology and therapeutics.

[136]  P. Baumann,et al.  Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes , 1992, Clinical pharmacology and therapeutics.

[137]  E. Leinonen,et al.  Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations. , 1992, Journal of clinical psychopharmacology.

[138]  M. Ingelman-Sundberg,et al.  Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population , 1992, Clinical pharmacology and therapeutics.

[139]  H. Manji,et al.  The pharmacologic treatment of depression. , 1991, The New England journal of medicine.

[140]  U. Meyer,et al.  Role of P450IID6, the target of the sparteine‐debrisoquin oxidation polymorphism, in the metabolism of imipramine , 1991, Clinical pharmacology and therapeutics.

[141]  T. Cooper,et al.  2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults. , 1991, Journal of clinical psychopharmacology.

[142]  J. Hallas,et al.  The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine , 1991, Clinical pharmacology and therapeutics.

[143]  K. Brøsen,et al.  Nonlinear Kinetics of Imipramine in Low and Medium Plasma Level Ranges , 1990, Therapeutic drug monitoring.

[144]  L. Balant,et al.  High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. , 1989, Therapeutic drug monitoring.

[145]  L. Schneider,et al.  Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. , 1988, Journal of clinical psychopharmacology.

[146]  S. Preskorn,et al.  Therapeutic drug monitoring of tricyclic antidepressants. , 1988, Clinical chemistry.

[147]  K. Brøsen,et al.  First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype , 1988, Clinical pharmacology and therapeutics.

[148]  G. Alexopoulos,et al.  Plasma 10-hydroxynortriptyline and renal function in elderly depressives , 1987, Biological Psychiatry.

[149]  M. Scheinin,et al.  Effects of nortriptyline and its 10-hydroxy metabolite on plasma noradrenaline (NA) concentrations, heart rate and blood pressure during intravenous NA infusion. , 1987, Methods and findings in experimental and clinical pharmacology.

[150]  E. Steiner,et al.  Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators , 1987, Clinical pharmacology and therapeutics.

[151]  L. Bertilsson,et al.  Clinical and biochemical effects during treatment of depression with nortriptyline: The role of 10‐hydroxynortriptyline , 1987, Clinical pharmacology and therapeutics.

[152]  Ö. Ericsson,et al.  Hydroxylation of desmethylimipramine: Dependence on the debrisoquin hydroxylation phenotype , 1987, Clinical pharmacology and therapeutics.

[153]  S. Otton,et al.  Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype , 1986, Clinical pharmacology and therapeutics.

[154]  M. Scheinin,et al.  Disposition of single oral doses of E‐10‐hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects , 1986, Clinical pharmacology and therapeutics.

[155]  L. Bertilsson,et al.  Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers , 1986, Clinical pharmacology and therapeutics.

[156]  P. Baumann,et al.  Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. , 1986, International clinical psychopharmacology.

[157]  L. Bertilsson,et al.  CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. , 1985, British journal of clinical pharmacology.

[158]  L. Bertilsson,et al.  Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio. , 1985, British journal of clinical pharmacology.

[159]  J. Amsterdam,et al.  Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients. Lack of correlation with therapeutic response. , 1985, Archives of general psychiatry.

[160]  B. Mellström,et al.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes , 1984, Clinical pharmacology and therapeutics.

[161]  E. Persad,et al.  The nonlinear kinetics of desipramine and 2‐hydroxydesipramine in plasma , 1984, Clinical pharmacology and therapeutics.

[162]  L. Bertilsson,et al.  Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects , 1984, Clinical pharmacology and therapeutics.

[163]  L. Bertilsson,et al.  The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. , 1983, British journal of clinical pharmacology.

[164]  P. Jatlow,et al.  Desipramine plasma concentration and antidepressant response. , 1982, Archives of general psychiatry.

[165]  S. Preskorn,et al.  Toxicity of tricyclic antidepressants--kinetics, mechanism, intervention: a review. , 1982, The Journal of clinical psychiatry.

[166]  L. Bertilsson,et al.  E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation , 1981, Clinical pharmacology and therapeutics.

[167]  M. Åsberg,et al.  SLOW HYDROXYLATION OF NORTRIPTYLINE AND CONCOMITANT POOR DEBRISOQUINE HYDROXYLATION: CLINICAL IMPLICATIONS , 1981, The Lancet.

[168]  L. Bertilsson,et al.  Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. , 1980, Life sciences.

[169]  F. Goodwin,et al.  Single-dose kinetics predict steady-state concentrations on imipramine and desipramine. , 1980, Archives of general psychiatry.

[170]  M. Åsberg,et al.  Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression , 1979, Clinical pharmacology and therapeutics.

[171]  L. Gram,et al.  Plasma Level Monitoring of Tricyclic Antidepressant Therapy , 1977, Clinical pharmacokinetics.

[172]  M. Åsberg,et al.  Relationship between Plasma Level and Therapeutic Effect of Nortriptyline , 1971, British medical journal.

[173]  F. Sjöqvist,et al.  Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. , 1967, Life sciences.

[174]  C. Peota.  Novel approach. , 2011, Minnesota medicine.

[175]  A. Conca,et al.  Therapeutic drug monitoring in psychiatry. , 2011, Pharmacopsychiatry.

[176]  J. Markowitz,et al.  PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder , 2010 .

[177]  E. Perucca,et al.  Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study , 2009, European Journal of Clinical Pharmacology.

[178]  I. Mahé,et al.  A Prospective Study , 2009 .

[179]  P. Weihe,et al.  The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. , 2008, British journal of clinical pharmacology.

[180]  Yang Wei-we.  A Review on , 2008 .

[181]  L. Balant,et al.  Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man , 2005, Archiv für Psychiatrie und Nervenkrankheiten.

[182]  K. Brøsen,et al.  Steady-state plasma levels of clomipramine and its metabolites: Impact of the sparteine/debrisoquine oxidation polymorphism , 2005, European Journal of Clinical Pharmacology.

[183]  M. Linder,et al.  Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice , 2005 .

[184]  P. Bech,et al.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism , 2004, European Journal of Clinical Pharmacology.

[185]  L. Balant,et al.  High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer , 2004, European Journal of Clinical Pharmacology.

[186]  Gordon L. Shaw.  Clinical implications , 2004, European Journal of Pediatrics.

[187]  L. Bertilsson,et al.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study , 2003, European Journal of Clinical Pharmacology.

[188]  J. Läuter,et al.  Comprehensive Survey of the Relationship Between Serum Concentration and Therapeutic Effect of Amitriptyline in Depression , 2002, Clinical pharmacokinetics.

[189]  L. Ståhle,et al.  Quantitative Pharmacogenetics of Nortriptyline , 2001, Clinical pharmacokinetics.

[190]  森田 幸代.  Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients : Impact of CYP2D6 genotype on the hydroxylation of nortriptyline , 2001 .

[191]  G R Wilkinson,et al.  A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. , 1998, The Journal of pharmacology and experimental therapeutics.

[192]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[193]  H. Manji,et al.  Comparative Tolerability Profiles of the Newer versus Older Antidepressants , 1994, Drug safety.

[194]  T. Buclin,et al.  Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. , 1992, Neuropsychobiology.

[195]  B. Pollock,et al.  Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[196]  M. Romkes,et al.  Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. , 1991, Biochemistry.

[197]  C. Mazure,et al.  Clinical implications of the pharmacokinetics of tricyclic antidepressants. , 1989, Psychopharmacology series.

[198]  L. Bertilsson,et al.  Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. , 1985, Therapeutic drug monitoring.

[199]  M. Åsberg,et al.  Monitoring Tricyclic Antidepressants , 1980, Therapeutic drug monitoring.

[200]  D. Laurence,et al.  Clinical Pharmacology & Therapeutics , 1980, Palgrave Macmillan UK.